|Dr. Claudio Albrecht||Chairman of the Exec. Board & CEO||N/A||N/A||1959|
|Mr. Mark Burgess Keatley MBA, MA, MPhil||CFO & Member of Exec. Board||N/A||N/A||1957|
|Dr. Barthold Piening||Chief Technical Operations Officer & Member of Exec. Board||N/A||N/A||1958|
|Ms. Leslie Isabelle Iltgen||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Sebastian Kramer-Bach||Exec. VP of Corp. Communication||N/A||N/A||1975|
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.
STADA Arzneimittel Aktiengesellschaft’s ISS Governance QualityScore as of April 1, 2018 is 3. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 1; Compensation: 2.